Comparison of diabetes drugs and their links to new and repeated kidney stones

The relationship between modern antidiabetic drug classes and stone risk in urolithiasis is not fully understood.

• Urolithiasis is linked to obesity, metabolic syndrome, and type 2 diabetes.
• Sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and dipeptidyl peptidase-4 inhibitors (DPP-4i) are modern antidiabetic drug classes.
• The study aimed to evaluate clinical-event evidence regarding these drug classes and their impact on urolithiasis outcomes.
• Findings regarding incident, recurrent, or severe urolithiasis outcomes remain unclear.

Simplified